Joenja (leniolisib) prior authorization for APDS
Customize your policy alerts
Sign up for all UnitedHealthcare policy alerts
Know when UnitedHealthcare releases new policies or updates existing guidance.
Monitor payer policy activity
Clinical pharmacy prior authorization and medical necessity criteria for use of Joenja (leniolisib) to treat activated PI3Kδ syndrome (APDS) in eligible members aged 12 and older; applies to UnitedHealthcare pharmacy programs.
No material clinical or coverage changes in this revision.
Coverage Criteria for Joenja (leniolisib)
Initial Therapy — Covered when ALL of the following are met
Covered when ALL of the following are met
Authorization will be issued for 12 months
Continuation/Reauthorization — Covered when ALL of the following are met
Covered when ALL of the following are met
Authorization will be issued for 12 months
Use of Joenja (leniolisib) for patients who are 12 years of age or who weigh less than 45 kg is not authorized under these criteria.
Initial Authorization Criteria
Initial Authorization — Initial therapy coverage conditions
Initial therapy coverage conditions
Approval/authorization will be issued for 12 months
Reauthorization / Continuation Criteria
Reauthorization — Reauthorization requires demonstrated clinical benefit and continued specialist prescribing.
Reauthorization requires demonstrated clinical benefit and continued specialist prescribing.
Authorization will be issued for 12 months
Key Coding and Demographics
Provider Requirements and Authorization Actions
Prior authorization required — approvals granted only when criteria met
Prior authorization is required; approvals are issued for 12 months when the initial or reauthorization clinical criteria are met, including confirmed APDS genetic diagnosis, required clinical manifestations, specialist prescribing, and age/weight thresholds.
- Authorization duration: 12 months
- Approval contingent on meeting all initial or reauthorization criteria (see coverage criteria)
Step therapy — prior trial/failure of standard of care required
Document a history of trial and failure, intolerance, or contraindication to standard of care for APDS (for example: antimicrobial prophylaxis, immunoglobulin replacement therapy, or immunosuppressive therapy) before initial approval.
- Step requirement applies to initial therapy only
- Must show trial and failure, intolerance, or contraindication to listed standard‑of‑care therapies
Required documentation — genetic, clinical, treatment history, prescriber, and weight
Provide documentation of a genetic test confirming an APDS‑associated variant in PIK3CD or PIK3R1, clinical findings consistent with APDS, prior treatments with reasons for trial/failure or intolerance, prescribing specialist credentials, baseline and on‑therapy clinical measures showing response, and patient weight.
- Genetic confirmation: APDS‑associated variant in PIK3CD or PIK3R1
- Clinical findings: e.g., recurrent infections, lymphadenopathy, hepatosplenomegaly, autoimmune cytopenias
- Prior treatments and reasons for failure/intolerance
- Prescriber must be a hematologist or immunologist
- Baseline and follow‑up measures (e.g., lymph node size, naïve B‑cell percentage)
- Document patient weight (must meet ≥45 kg threshold)
Denial triggers for initial authorization
Initial authorization may be denied if the record does not document an APDS diagnosis confirmed by an APDS‑associated genetic variant, lacks required clinical manifestations consistent with APDS, fails to show trial/failure/intolerance to standard of care, is prescribed by a provider who is not a hematologist or immunologist, or the patient is under 12 years of age or weighs <45 kg.
- No documented genetic confirmation of APDS (PIK3CD or PIK3R1)
- Absence of required clinical manifestations (e.g., recurrent infections, lymphadenopathy)
- No documentation of prior trial/failure/intolerance to standard of care
- Prescriber not a hematologist or immunologist
- Patient age <12 years or weight <45 kg
Denial triggers for reauthorization
For reauthorization, requests may be denied if there is no documented positive clinical response to therapy, the prescriber is not a hematologist or immunologist, or the patient’s weight is <45 kg.
- Lack of documented positive clinical response (e.g., reduced lymph node size, increased naïve B‑cell percentage, fewer/severe infections, fewer hospitalizations)
- Prescriber not a hematologist or immunologist
- Patient weight <45 kg
Step Therapy Requirements
| Step | Requirement |
|---|---|
| 1 | Documented history of trial and failure, intolerance, or contraindication to current standard of care for APDS (e.g., antimicrobial prophylaxis, immunoglobulin replacement therapy, immunosuppressive therapy) prior to initial approval. |
Quantity Limits and Dispensing
Definitions
Background
Activated phosphoinositide 3-kinase delta syndrome (APDS) is a rare primary immunodeficiency caused by pathogenic variants in PIK3CD or PIK3R1 that lead to PI3Kδ hyperactivity and abnormal B- and T‑cell development, manifesting as lymphoproliferation, recurrent infections, autoimmune cytopenias, and increased malignancy risk. Diagnosis is confirmed by genetic testing demonstrating an APDS‑associated variant.
Standard management includes antimicrobial prophylaxis, immunoglobulin replacement, immunosuppressive therapy, and in select cases hematopoietic stem cell transplant. Leniolisib (Joenja) is a selective PI3Kδ inhibitor indicated for the treatment of APDS in patients aged 12 years and older, and this policy specifies clinical and documentation requirements for prior authorization and reauthorization.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.